IMUX vs ABBV vs GILD vs BIIB vs JPM

For growth investors, AbbVie Inc.

(ABBV) is the stronger pick with 8. 6% revenue growth year-over-year, versus 1. 4% for Biogen Inc. (BIIB). JPMorgan Chase & Co. (JPM) offers the better valuation at 15. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Immunic, Inc. (IMUX) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 15. 6x versus AbbVie Inc. at 94. 8x. On forward P/E, Biogen Inc. is actually cheaper at 13. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 1. 08x versus Gilead Sciences, Inc. 's 3. 60x — a reasonable growth-adjusted valuation.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +121. 1%, compared to -90. 8% for Immunic, Inc. (IMUX). Over 10 years, the gap is even starker: JPM returned +465. 8% versus IMUX's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 14β versus Immunic, Inc. 's 1. 80β — meaning IMUX is approximately 1222% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Biogen Inc. (BIIB) carries a lower debt/equity ratio of 38% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AbbVie Inc.

(ABBV) is pulling ahead at 8. 6% versus 1. 4% for Biogen Inc. (BIIB). On earnings-per-share growth, the picture is similar: Gilead Sciences, Inc. grew EPS 1684% year-over-year, compared to -21. 1% for Biogen Inc.. Over a 3-year CAGR, GILD leads at 2. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Gilead Sciences, Inc.

(GILD) is the more profitable company, earning 28. 9% net margin versus 0. 0% for Immunic, Inc. — meaning it keeps 28. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GILD leads at 39. 7% versus 0. 0% for IMUX. At the gross margin level — before operating expenses — GILD leads at 78. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 1. 08x versus Gilead Sciences, Inc. 's 3. 60x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Biogen Inc. (BIIB) trades at 13. 7x forward P/E versus 480. 4x for Gilead Sciences, Inc. — 466. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GILD: 26. 8% to $159. 56.

In this comparison, ABBV (2.

9% yield), GILD (2. 5% yield), JPM (1. 9% yield) pay a dividend. IMUX, BIIB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 14), 2. 9% yield, +362. 2% 10Y return). Immunic, Inc. (IMUX) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +362. 2%, IMUX: -99. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IMUX (Healthcare) and ABBV (Healthcare) and GILD (Healthcare) and BIIB (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: IMUX is a small-cap quality compounder stock; ABBV is a large-cap quality compounder stock; GILD is a mid-cap quality compounder stock; BIIB is a mid-cap quality compounder stock; JPM is a large-cap deep-value stock. ABBV, GILD, JPM pay a dividend while IMUX, BIIB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.